FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 442 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... July 5, 2021 ESMO Breast Cancer Congress 2023 April 17, 2023 Virtual Reality Could Reduce Stress for Chemo Patients, Improving Cancer Outcomes January 23, 2020 Blood test could tailor treatment after surgery July 14, 2021 Load more HOT NEWS Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive... Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar 8-Year-Old Cancer Survivor Celebrates Recovery By Donating Her Birthday Gifts To...
